// App-Quantinova.ai

TCT-1 : Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

Researchers

Presenter

  • Sorin Brener

Principal Investigators

  • Patrick Serruys

  • Martin Leon

  • Marie-Claude Morice

  • David Kandzari

  • Roxana Mehran

  • A. Pieter Kappetein

  • Joseph Sabik

  • Yangbo Liu

  • Ovidiu Dressler

  • Ori Ben-Yehuda

  • Gregg Stone

Medical Centers

  • Imperial College, London, United Kingdom

  • CERC, Massy, France

  • Piedmont Heart Institute, Atlanta, Georgia, United States

  • Cardiovascular Research Foundation, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States

  • New York Methodist Hospital, Brooklyn, New York, United States

  • Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, United States

  • Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands

  • Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York, United States

  • Cardiovascular Research Foundation, New York, New York, United States

Locations

  • United Kingdom

  • United States

  • Netherlands

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved